Field evaluation of calypte's AWARE™ Blood Serum Plasma (BSP) and Oral Mucosal Transudate (OMT) rapid tests for detecting antibodies to HIV-1 and 2 in plasma and oral fluid

Open AIDS Journal

Volumn 3, Issue , 2009, Pages 14-18

  Alemnji, George A ^a   Ngulefac, Gisele A ^a   Ndumbe, Peter M ^a   Asonganyi, Tazoacha ^a  

^a UNIVERSITY OF YAOUNDÉ I   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; GOLD STANDARD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MOUTH MUCOSA; PRIORITY JOURNAL; SERUM;

EID: 77953390455     PISSN: None     EISSN: 18746136     Source Type: Journal    
DOI: 10.2174/1874613600903010014     Document Type: Article

References (27)

1. Jacobson LP, Li R, Phair J, et al. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression. Am J Epidemiol 2002; 155: 760-770 (Pubitemid 34297657)
2. 6 /l. AIDS 2002; 16:1371-1381
3. Tamashiro H, Maskill W, Emmanuel J, Fauquex A, Sato P, Heymann D. Reducing the cost of HIV antibody testing. Lancet 1993; 342:87-90. (Pubitemid 23192427)
4. Constantine NT, Zink H. HIV testing technologies after two decades of evolution. Indian J Med Res 2005; 121:519-538 (Pubitemid 40703859)
5. UNAIDS/WHO. Guidelines for using HIV testing technologies in surveillance: Selection, evaluation and implementation. UNAIDS/ 01.22E. WHO/CDS/CSR/EDC 2001; 16.
6. Keenan PA, Keenan JM, Branson BM. Rapid HIV testing. Wait time reduced from days to minutes. Postgrad Med 2005; 117: 47-52.
7. Lee S, Hu J, Tang S, et al. Evaluation of FDA licensed HIV assays using plasma from Cameroonian blood donors. J Med Virol 2006; 78 (Suppl 1): S22-3. (Pubitemid 43993460)
8. Constantine NT, Callahan JD, Watts DM. Time for HIV-1/HIV-2 combination tests? J Virol Methods 1989; 26:219-221
9. Gurtler LG, Zekeng L, Tsague JM, et al. HIV-1 subtype O: epidemiology, pathogenesis, diagnosis, and perspectives of the evolution of HIV. Arch Virol Suppl 1996; 11:195-202. (Pubitemid 126446191)
10. Takeshisa J, Zekeng L, Ido E, et al. Various types of HIV mixed infections in Cameroon. Virology 1998; 245:1-10. (Pubitemid 28384072)
11. Nkengasong JN, Janssens W, HeyndrickxnL, et al. Genotypic subtypes of HIV-1 in Cameroon. AIDS 1994; 8: 1405-1412
12. Tscherning-Casper C, Dolcini G, Mauclere P, et al. Evidence of the existence of a new circulating recombinant form of HIV type 1 subtype A/J in Cameroon. The European Network on the Study of In Utero Transmission of HIV-1. AIDS Res Hum Retroviruses 2000; 16:1313-1318 (Pubitemid 30679936)
13. Ndembi N, Takehisa J, Zekeng L, et al. Genetic diversity of HIV type 1 in rural eastern Cameroon. J Acquir Immune Defic Syndr 2004; 37:1641-1650 (Pubitemid 39658207)
14. Fonjungo PN, Mpoudi EN, Torimiro JN, et al. Presence of diverse human immunodeficiency virus type 1 viral variants in Cameroon. AIDS Res Hum Retroviruses 2000; 16:1319-1324 (Pubitemid 30679937)
15. Ahidjo A, Souquieres S, Njinku B, et al. HIV -1 group N among HIV-1 seropositive individuals in Cameroon. AIDS 2000; 14: 2623-2625 (Pubitemid 30840062)
16. Loussert-Ajaka A, Ly TD, Chaix ML, et al. HIV-1/HIV-2 Seronegativity in HIV-1 subtype O infected patients. Lancet 1994; 343:1393-1394 (Pubitemid 2082095)
17. Sangare KA, Koffi AR, Coulibaly IM, Doulourou C. Could saliva be used to detect HIV seroconversion? Sante 1997; 7: 303-307
18. Tamashiro H, Constantine NT. Serological diagnosis of HIV infection using oral fluid samples. Bull World Health Organ 1994; 72:135-143 (Pubitemid 24090729)
19. Delaney KP, Branson BM, Uniyal A, et al. Performance of an oral fluid rapid HIV-1/2 test: experience from four CDC studies. AIDS 2006; 20:1655-1660 (Pubitemid 44162408)
20. Calypte Biomedical Corporation 16290 SW Upper Boones Ferry Rd. Portland, OR, 97224, USA.
21. UNAIDS/WHO recommendations. The importance of simple/rapid assays in HIV testing. Weekly Epidemiologic Record 1998; 73:321-328.
22. Calypte Biomedical Corporation. AWARE™ HIV- 1 / 2 OMT manufacturer's instructions. 2005; LN 20629.00.
23. Wirachsilp P, Kantakamalakul W, Foongladda S, et al. Surveillance of subtype and genetic variation of the circulating strains of HIV-1 in Thailand. Southeast Asian J Trop Med Public Health 2007; 38:814-827
24. Peeters M, Toure-Kane C, Nkengasong JN. Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. AIDS 2003; 17:2547-2560 (Pubitemid 38402333)
25. Urassa W, Ocheng D, Kasubi M. Field evaluation of Aware™ HIV-1/2 OMT rapid tests for the detection of antibodies to HIV 1+2 in human oral mucosal transudate among AMREF ANGAZA VCT clients in Tanzania. Poster presented at the IAS Conference: Sydney 2007.
26. Viljoen JI, Moodley PI, Venketsamy T. Field Evaluation of the Calypte® Aware™ HIV-1/2 OMT Rapid Test for the detection of antibodies to HIV-1/2 in Oral Mucosal Transudate. Poster presented at the 3rd South Africa AIDS Conference 2007.
27. Centers for Disease Control and Prevention (CDC). False-positive oral fluid rapid HIV tests-New York City, 2005-2008. MMWR Morb Mortal Wkly 2008; 57: 660-665